STOCK TITAN

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
AbCellera (ABCL) to announce first quarter 2024 financial results on May 7, 2024, with an earnings conference call scheduled. Investors can access a live audio webcast and replay on AbCellera's Investor Relations website.
Positive
  • None.
Negative
  • None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Inquiries

Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005

Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

AbCellera (ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024.

The earnings conference call for AbCellera (ABCL) is scheduled at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on May 7, 2024.

Investors can access the live audio webcast of the earnings conference for AbCellera (ABCL) through a link that will be posted on AbCellera's Investor Relations website.

Yes, a replay will be available through the same link following the conference call for AbCellera (ABCL).
AbCellera Biologics Inc

NASDAQ:ABCL

ABCL Rankings

ABCL Latest News

ABCL Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Vancouver

About ABCL

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’